Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2019 Jun 22;7(8):2790–2800.e15. doi: 10.1016/j.jaip.2019.06.011

Figure 4.

Figure 4.

Various complete remission rates in LRBA-deficient patients after treatment with abatacept according to dosing interval. A, The complete remission (CR) rates in patients received abatacept with one-week or two-weeks interval in comparison to four-weeks. C, The percentages of CR or partial remission (PR) rate in LRBA-deficient patients in terms of dose interval. ** p<.01, 1-way ANOVA test, * p<.05, Chi-square test.